Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 2/2018

30.09.2017 | Assisted Reproduction Technologies

The value of delaying hCG administration to enable maturation of medium-sized follicles in patients undergoing superovulation for IVF/ICSI

verfasst von: Awoniyi O. Awonuga, Karen Wheeler, Mili Thakur, Roohi Jeelani, Michael P. Diamond, Elizabeth E. Puscheck

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of the study is to determine whether continued stimulation of mature follicles to allow “catch up” growth of medium-sized follicles in assisted reproductive technology compromises the clinical pregnancy (CPR) and live birth (LBR) rates in IVF/ICSI cycles.

Methods

This retrospective cohort study reviewed 200 first IVF ± ICSI cycles out of a total of 340 cycles with complete data. Women underwent stimulation protocols with gonadotropins (Gn) and GnRH antagonist. Treatment cycles were divided into two groups (Gp): hCG administration delayed despite the presence of two mature follicles, defined as ≥ 18 mm [Gp1, n = 79] and hCG administration given when there were two mature follicles [Gp2, n = 121].

Results

The patients in Gp1 were significantly younger than those in Gp2 [32.9 (4.5) vs. 34.3 (4.8), p = 0.04] and needed a median of one more day of superovulation before ovulation was triggered with hCG. The extra days was associated with the use of 450 [75–2025] more Gn, such that at the time the hCG was administered, patient’s in group 1 had developed significantly greater number of follicles ≥ 18 mm [mean (SD), 4.9 (1.8) vs. 3.4 (1.7), p < 0.0001]. The clinical pregnancy (48.1 vs. 38.0%, [OR (95% CI)] [1.6 (1.0–2.5), p = 0.09]) and live birth (43.0 vs. 35.5%, [1.4 (0.9–2.3), p = 0.21]) rates per cycle started were not significantly different between the two groups. Forward stepwise logistic regression showed that only maternal age (p = 0.04) influenced clinical pregnancy rates (OR = 0.88, CI 0.78–0.99) and only the number of days for superovulation influenced live birth rates (OR = 0.65, CI 0.486–0.869).

Conclusion

This study demonstrated that delaying hCG administration to allow further growth of the medium-sized follicles added further days of superovulation and cost without improvement in CPR and LBR.
Literatur
1.
Zurück zum Zitat de Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, European Ivf-monitoring Consortium ftESoHR, et al. Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE. Hum Reprod. 2010;25(8):1851–62.CrossRefPubMed de Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, European Ivf-monitoring Consortium ftESoHR, et al. Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE. Hum Reprod. 2010;25(8):1851–62.CrossRefPubMed
2.
Zurück zum Zitat Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002;78(5):1025–9.CrossRefPubMed Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002;78(5):1025–9.CrossRefPubMed
3.
Zurück zum Zitat Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril. 2003;79(4):873–80.CrossRefPubMed Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril. 2003;79(4):873–80.CrossRefPubMed
4.
Zurück zum Zitat Meniru GI, Craft IL. Utilization of retrieved oocytes as an index of the efficiency of superovulation strategies for in-vitro fertilization treatment. Hum Reprod. 1997;12(10):2129–32.CrossRefPubMed Meniru GI, Craft IL. Utilization of retrieved oocytes as an index of the efficiency of superovulation strategies for in-vitro fertilization treatment. Hum Reprod. 1997;12(10):2129–32.CrossRefPubMed
5.
Zurück zum Zitat Jaffe SB, Jaffe LH, Jewelewicz R. Incidence of severe ovarian hyperstimulation syndrome with extremely elevated serum estrogen levels. Gynecol Obstet Investig. 1993;35(4):222–7.CrossRef Jaffe SB, Jaffe LH, Jewelewicz R. Incidence of severe ovarian hyperstimulation syndrome with extremely elevated serum estrogen levels. Gynecol Obstet Investig. 1993;35(4):222–7.CrossRef
6.
Zurück zum Zitat Patrizio P, Sakkas D. From oocyte to baby: a clinical evaluation of the biological efficiency of in vitro fertilization. Fertil Steril. 2009;91(4):1061–6.CrossRefPubMed Patrizio P, Sakkas D. From oocyte to baby: a clinical evaluation of the biological efficiency of in vitro fertilization. Fertil Steril. 2009;91(4):1061–6.CrossRefPubMed
7.
Zurück zum Zitat Tan SL, Balen A, el Hussein E, Mills C, Campbell S, Yovich J, et al. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization. Fertil Steril. 1992;57(6):1259–64.CrossRefPubMed Tan SL, Balen A, el Hussein E, Mills C, Campbell S, Yovich J, et al. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization. Fertil Steril. 1992;57(6):1259–64.CrossRefPubMed
8.
Zurück zum Zitat Dimitry ES, Bates SA, Oskarsson T, Margara R, Winston RM. Programming in vitro fertilization for a 5- or 3-day week. Fertil Steril. 1991;55(5):934–8.CrossRefPubMed Dimitry ES, Bates SA, Oskarsson T, Margara R, Winston RM. Programming in vitro fertilization for a 5- or 3-day week. Fertil Steril. 1991;55(5):934–8.CrossRefPubMed
9.
Zurück zum Zitat Abdalla HI, Baber RJ, Leonard T, Kirkland A, Mitchell A, Power M, et al. Timed oocyte collection in an assisted conception programme using GnRH analogue. Hum Reprod. 1989;4(8):927–30.CrossRefPubMed Abdalla HI, Baber RJ, Leonard T, Kirkland A, Mitchell A, Power M, et al. Timed oocyte collection in an assisted conception programme using GnRH analogue. Hum Reprod. 1989;4(8):927–30.CrossRefPubMed
10.
Zurück zum Zitat Chen Y, Zhang Y, Hu M, Liu X, Qi H. Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis. Gynecol Endocrinol. 2014;30(6):431–7.CrossRefPubMed Chen Y, Zhang Y, Hu M, Liu X, Qi H. Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis. Gynecol Endocrinol. 2014;30(6):431–7.CrossRefPubMed
11.
Zurück zum Zitat Morley L, Tang T, Yasmin E, Hamzeh R, Rutherford AJ, Balen AH. Timing of human chorionic gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized controlled trial. Hum Fertil (Camb). 2012;15(3):134–9.CrossRef Morley L, Tang T, Yasmin E, Hamzeh R, Rutherford AJ, Balen AH. Timing of human chorionic gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized controlled trial. Hum Fertil (Camb). 2012;15(3):134–9.CrossRef
12.
Zurück zum Zitat Tremellen KP, Lane M. Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Hum Reprod. 2010;25(5):1219–24.CrossRefPubMed Tremellen KP, Lane M. Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Hum Reprod. 2010;25(5):1219–24.CrossRefPubMed
13.
Zurück zum Zitat Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet. 1984;2(8414):1284–5.CrossRefPubMed Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet. 1984;2(8414):1284–5.CrossRefPubMed
14.
Zurück zum Zitat Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9(5):788–91.CrossRefPubMed Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9(5):788–91.CrossRefPubMed
15.
Zurück zum Zitat Clark L, Stanger J, Brinsmead M. Prolonged follicle stimulation decreases pregnancy rates after in vitro fertilization. Fertil Steril. 1991;55(6):1192–4.CrossRefPubMed Clark L, Stanger J, Brinsmead M. Prolonged follicle stimulation decreases pregnancy rates after in vitro fertilization. Fertil Steril. 1991;55(6):1192–4.CrossRefPubMed
16.
Zurück zum Zitat Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril. 2004;82(1):102–7.CrossRefPubMed Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril. 2004;82(1):102–7.CrossRefPubMed
17.
Zurück zum Zitat Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000;15(3):526–31.CrossRefPubMed Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000;15(3):526–31.CrossRefPubMed
18.
Zurück zum Zitat Felberbaum RE, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod. 2000;15(5):1015–20.CrossRefPubMed Felberbaum RE, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod. 2000;15(5):1015–20.CrossRefPubMed
19.
Zurück zum Zitat Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, et al. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod. 2001;16(12):2533–9.CrossRefPubMed Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, et al. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod. 2001;16(12):2533–9.CrossRefPubMed
20.
Zurück zum Zitat de Jong D, Macklon NS, Fauser BC. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the “follicle-stimulating hormone window” combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril. 2000;73(5):1051–4.CrossRefPubMed de Jong D, Macklon NS, Fauser BC. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the “follicle-stimulating hormone window” combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril. 2000;73(5):1051–4.CrossRefPubMed
21.
Zurück zum Zitat Yoldemir T, Fraser IS. The effect of retrieved oocyte count on pregnancy outcomes in an assisted reproduction program. Arch Gynecol Obstet. 2010;281(3):551–6.CrossRefPubMed Yoldemir T, Fraser IS. The effect of retrieved oocyte count on pregnancy outcomes in an assisted reproduction program. Arch Gynecol Obstet. 2010;281(3):551–6.CrossRefPubMed
Metadaten
Titel
The value of delaying hCG administration to enable maturation of medium-sized follicles in patients undergoing superovulation for IVF/ICSI
verfasst von
Awoniyi O. Awonuga
Karen Wheeler
Mili Thakur
Roohi Jeelani
Michael P. Diamond
Elizabeth E. Puscheck
Publikationsdatum
30.09.2017
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 2/2018
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-017-1056-6

Weitere Artikel der Ausgabe 2/2018

Journal of Assisted Reproduction and Genetics 2/2018 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.